期刊文献+

依帕司他治疗2型糖尿病早期肾病的临床研究 被引量:3

下载PDF
导出
摘要 目的观察依帕司他治疗2型糖尿病早期肾病的效果。方法将57例伴有微量白蛋白尿的2型糖尿病患者随机分为依帕司他治疗组(观察组,30例)和常规治疗组(对照组,27例),治疗前后测定尿微量白蛋白排泄率(urinary albumin ex-cretion rates,UAER)、血浆内皮素-1(endothelin,ET-1)及血清一氧化氮(NO)水平。结果与治疗前比较,观察组UAER及ET-1均显著降低(P<0.01),NO明显升高(P<0.01)。治疗过程中未出现明显不良反应。对照组UAER、ET-1及N0与治疗前比较差异无统计学意义(P>0.05)。结论依帕司他能减少2型糖尿病肾病(diabetic nephropathy,DN)患者尿微量白蛋白的排泄。
作者 戚文群
出处 《实用临床医药杂志》 CAS 2011年第21期102-102,106,共2页 Journal of Clinical Medicine in Practice
  • 相关文献

参考文献4

  • 1陆再英,钟南山.内科学[M].北京:人民卫生出版社,2008:121.
  • 2Agarwal R. Add on angiotensin receptor blockade with maximized ACE inhibition[ J]. Kidney Int, 2001, 59(6) : 2282.
  • 3Is O K, Tada H, Kubold K, et al. Long2 term effect ofepaL- restat, an aLdose reductaseinhibitor, on the development ofincip ient diabetic nephropathy in type 2diabetic patients [ J ]. J Diabetes CompLications, 2001, 15 (7) : 241.
  • 4郑琪蓉,苏青.依帕司他的药理作用及临床应用[J].中国新药与临床杂志,2006,25(11):876-884. 被引量:40

二级参考文献51

  • 1van HEYNINGEN R. Formation of polyols by the lens of the rat with 'sugar' cataract[J]. Nature, 1959, 184:194-195.
  • 2SUZEN S, BUYUKBINGOL E. Recent studies of aldose reductase enzyme inhibition for diabetic complications[J]. Curt Med Chem, 2003, 10(15):1329-1352.
  • 3QUINN MT, GAUSS KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases[J]. J Leukoc Biol, 2004, 76(4):760-781.
  • 4BROWNLEE M, The pathobiology of diabetic complications: a unifying mechanism[J]. Diabetes, 2005, 54(6) : 1615-1625.
  • 5VINCENT AM, FELDMAN EL. New insights into the mechanisms of diabetic neuropathy[J]. Rev Endocr Metab Disord, 2004,5 (3) : 227 -236.
  • 6BOULTON AJM, MALIK RA, AREZZO JC, et al. Diabetic somatic neuropathies[J]. Diabetes Care, 2004, 27(6) : 1458-1486.
  • 7EL-KABBANI O, DARMANIN C, CHUNG RP. Sorbitol dehydrogenase: structure, iunction and ligand design[J]. Curt Med Chem, 2004,11 (4) :465-476.
  • 8PETRASH JM. All in the family: aldose reductase and closely related aldo-keto reductase[J]. Cell Mol Life Sci, 2004, 61 (7-8 ) : 737-749.
  • 9EL-KABBANI O, RUIZ F, DARMANIN C, et al. Aldose reductase structures: implications for mechanism and inhibition[J].Ceil Moi Life Sci, 2004, 61 (7-8):750-762.
  • 10PODJARNY A, CACHAU RE, SCHNEIDER T, et al. Subatomic and atomic crystallographic studies of aldose reductase:implications for inhibitor binding[J]. Cell Mol Life Sci, 2004,61(7-8) :763-773.

共引文献1726

同被引文献32

  • 1刘长山,孙丽萍,李兆欣,柳林,王秀军,刘海霞,逄力男.依帕司他对糖尿病大鼠肾脏醛糖还原酶活性、细胞凋亡及超微结构的影响[J].中国新药杂志,2007,16(6):454-457. 被引量:1
  • 2曾文新,郑惠鹏,黄伟平.依帕司他对糖尿病肾病患者肾功能及尿蛋白的影响[J].广东医学,2007,28(7):1166-1167. 被引量:4
  • 3Caramori ML, Mauer M. Diabetes and nephropathy [J]. CurrOpin Nephrol Hypertens, 2003,12(2) : 273-282.
  • 4Dronavalli S, Duka I, Bakris GL. The pathogenesis ofdiabetic neophropathy [ J ]. Nat Clin Pract Endocrinol Metab,2008,4(8):444-452.
  • 5Ziyadeh KN, Sharma K. Overview: Combating diabeticnephropathy [J]. J Am Soc Nephro, 2003,14(5) : 1355-1357.
  • 6Packham DK, Alves TP, Dwyer JP, et al. Relative incidenceof ESRD versus cardiovascular mortality in proteinuric type 2diabetes and nephropathy: Results from the DIAMETRIC(Diabetes Mellitus Treatment for Renal InsufficiencyConsortium) database [J]. Am J Kidney Dis, 2012,59 (1):75-83.
  • 7American Diabetes Association. Position Statement: Diabeticneophropathy [ J ]. Diabetes care, 1998 ,21 : s50.
  • 8Craven PA, DeRubertis FR. Sorbinil suppresses glomerularprostaglandin production in the streptozotocin diabetic rat [J].Metabolism, 1989,38(7) :649-654.
  • 9Derylo B,Babazono T, Glogowski E, et ai. High glucose-induced mesangial cell altered contractility: Role of the polyolpathway[J]. Diabetologia, 1998,41(5) :507-515.
  • 10Ishii H, Tada H, Isogai S. An aldose reductase inhibitorprevents glucose - induced increase in transforming growthfactor-beta and protein kinase C activity in cultured mesangialcells [J]. Diabetologia, 1998 ,41 (3) : 362-364.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部